Korea Drug Development Fund
Korea Drug Development Fund (KDDF) is a South Korean government-funded R&D program that provides preclinical and clinical-stage grants to Korean biotech ventures and pharmaceutical companies, with Phase 2 (2026-2030) prioritizing clinical approvals and AI-based drug development.
- Company typePrivate
- Founded2011
- HeadquartersSeoul, South Korea
- Headcount—
- GTM typeB2B
- OfferingServices
What Korea Drug Development Fund does
The Korea Drug Development Fund (KDDF) is a South Korean government-funded national drug R&D program established in 2011, headquartered at 9F, 137 Mapo-daero, Mapo-gu, Seoul. KDDF operates as a 20-year, two-phase initiative: Season 1 (2011-2020) achieved 230% of its target, producing 72 investigational new drug (IND) approvals and 50 technology transfers valued at 16.1 trillion won. The program supports Korean biotech ventures and pharmaceutical companies through preclinical and clinical-stage grant funding, evaluated by an investment review committee of approximately 100 experts nominated by multiple government ministries.
KDDF does not sell commercial products or services. Its revenue model is government appropriations redistributed as R&D grants, with portfolio value capture occurring indirectly through facilitated technology transfers and licensing deals (e.g., LigaChem Biosciences' 2.25 trillion won TROP2 ADC export to Johnson & Johnson Innovative Medicine). The Phase 2 program (2026-2030) shifts emphasis toward clinical-stage project support, AI-based new drug development, reduced matching burden ratios for smaller companies, and generation of tangible outcomes including early clinical approvals and global blockbuster drugs.
The fund's distribution operates through direct grant funding evaluated via the investment review committee, technology transfer facilitation with global pharmaceutical partners, and ecosystem engagement at events including the JP Morgan Healthcare Conference. In 2025, KDDF secured combined $986 million in five-year commitments from Roche ($486 million) and Eli Lilly ($500 million) to expand clinical trials and support Korean biotech ventures, aligning with Seoul's ambition to become a top-five global biopharma power by 2030. Recent grant recipients include Proteina (2 billion won for osteoarthritis candidate PRT-101, June 2026), Samjin Pharmaceutical (Phase 1 MRGPRX2 inhibitor SJN314), and Curogen Technology (fifth national grant for autoimmune disease programs).
Korea Drug Development Fund firmographics
Firmographics- Name
- Korea Drug Development Fund
- Legal name
- Korea Drug Development Fund
- Website
- https://eng.kddf.org
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Short description
- Korea Drug Development Fund (KDDF) is a South Korean government-funded R&D program that provides preclinical and clinical-stage grants to Korean biotech ventures and pharmaceutical companies, with Phase 2 (2026-2030) prioritizing clinical approvals and AI-based drug development.
- Ownership category
- akta.pro rank
Korea Drug Development Fund industry classification
Industry- Product category
- Government R&D Funding for Drug Development
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
- akta.pro secondary industries
- Research & Science Grantmaking Foundations (BPAGAKAI), National/Regional Development Finance Institutions (DFIs) (FSABAKAB)
Keywords
Where Korea Drug Development Fund is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
Korea Drug Development Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Government-funded R&D program: KDDF operates as a 10-year government-funded drug development program with two phases. Phase 1 achieved 230% of target with 72 investigational new drug approvals and 50 technology transfers worth 16.1 trillion won.
- Grant funding to biotech companies: KDDF provides preclinical research grants to Korean biotech companies, such as the 2 billion won grant to Proteina for osteoarthritis candidate PRT-101, with government contributing 1.5 billion won over 24 months.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Korea Drug Development Fund product offering
Product offeringCore offering
Korea Drug Development Fund (KDDF) is a government-funded national R&D program that provides preclinical and clinical-stage funding support to Korean biotech ventures and pharmaceutical companies developing new drugs. The fund selects projects through an investment review committee process and supports companies across the drug development pipeline, from preclinical research grants to IND-enabling work and clinical-stage project support. KDDF also facilitates technology transfers and licensing deals between supported Korean companies and global pharmaceutical partners.
Product overview
The Korea Drug Development Fund (KDDF) is a government-funded national drug R&D program operating in two phases: Season 1 (2011-2020) and Season 2 (2021-2030). As a public R&D funding organization rather than a commercial product company, KDDF supports drug development projects through grants and investment review processes. The fund focuses on clinical-stage projects, investigational new drug approvals, and technology transfers. KDDF does not offer commercial products or services to end users; its activities include providing preclinical research grants, supporting IND applications, facilitating technology transfers, and expanding AI-based new drug development initiatives.
Differentiator
Problem solved
Functional benefit
Products and services
- KDDF Phase 2 Program (2026-2030) Government-funded R&D support program for Korean biotech companies, focusing on clinical-stage project support and AI-based new drug development during the 2026-2030 period. For biotech ventures and pharmaceutical companies seeking clinical-stage funding and AI-based drug development support.
- Preclinical Research Grants Grants provided to Korean biotech companies for preclinical-stage drug development research, with example of 2 billion won grant to Proteina for osteoarthritis candidate PRT-101, where the government contributes 1.5 billion won over a 24-month program. For Korean biotech ventures developing preclinical drug candidates.
- Clinical-Stage Project Support Funding and institutional support for Korean biotech companies advancing drug candidates through clinical trial phases, including support for investigational new drug (IND) applications and clinical trial costs. For Korean pharmaceutical and biotech companies conducting clinical-stage drug development.
- Technology Transfer Facilitation Facilitation of technology transfer and licensing deals between supported Korean biotech companies and global pharmaceutical partners, exemplified by the 2.25 trillion won LigaChem Biosciences TROP2 ADC LCB84 deal with Johnson & Johnson Innovative Medicine. For Korean biotech companies seeking global pharmaceutical licensing partners.
Quantifiable outcome
- 230% of target achieved in Phase 1
- +3 more outcomes
Companies that use Korea Drug Development Fund
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
Korea Drug Development Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Korea Drug Development Fund partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship, minor and core.
- Johnson & Johnson Innovative MedicineflagshipJohnson & Johnson Innovative Medicine acquired LigaChem Biosciences' TROP2-targeted ADC LCB84 for 2.25 trillion won in one of the largest biotech export deals from Korea, demonstrating KDDF's success in facilitating high-value technology transfers.
- Seoul National University HospitalminorSeoul National University Hospital is conducting the phase 1 clinical trial for Samjin Pharmaceutical's SJN314 MRGPRX2 inhibitor, which originated from KDDF-supported preclinical research.
- Multiple Government MinistriescoreThe KDDF investment review committee is composed of experts recommended by multiple government ministries, providing objective judgment on project feasibility and support scale for government-funded R&D programs.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Korea Drug Development Fund competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Korea Drug Development Fund social profiles
Digital presenceKorea Drug Development Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
Korea Drug Development Fund leadership team
Management profileNumber of profiles
Korea Drug Development Fund funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Korea Drug Development Fund M&A and investment
M&A and investmentM&A
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Korea Drug Development Fund
What does Korea Drug Development Fund do?
Korea Drug Development Fund (KDDF) is a government-funded national R&D program that provides preclinical and clinical-stage funding support to Korean biotech ventures and pharmaceutical companies developing new drugs. The fund selects projects through an investment review committee process and supports companies across the drug development pipeline, from preclinical research grants to IND-enabling work and clinical-stage project support. KDDF also facilitates technology transfers and licensing deals between supported Korean companies and global pharmaceutical partners.
Is Korea Drug Development Fund a public or private company?
Korea Drug Development Fund is a private company. It is classified as state government owned and is currently operating.
When was Korea Drug Development Fund founded?
Korea Drug Development Fund was founded in 2011.
Where is Korea Drug Development Fund based?
Korea Drug Development Fund is headquartered in Seoul, South Korea, in the Asia region.
How does Korea Drug Development Fund make money?
Two revenue lines are on record. Government-funded R&D program is the primary driver. The others are grant funding to biotech companies.
Does Korea Drug Development Fund have an API?
No public API is recorded for Korea Drug Development Fund.
What industry is Korea Drug Development Fund in?
Korea Drug Development Fund's product category is Government R&D Funding for Drug Development. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 5417 and its SIC code is 8731.